All articles by Globaldata Healthcare
Global has decades of experience in being the trusted, gold standard intelligence provider to leading pharmaceutical brands, manufacturers, and suppliers, helping them to make faster, more informed decisions
HPV vaccine reduces cervical cancer risk by 87%, but uptake remains poor
While HPV vaccination rates are high in some countries, in other countries vaccine uptake is poor.
Breast cancer awareness month: Remembering the burden of this disease
According to the World Health Organization (WHO), breast cancer is the second most common cancer in the world and the most common cancer in women worldwide, accounting for 25% of all incident cases of female cancers.
US leads actively recruiting clinical trials for Covid-19
As new strains of COVID-19 continue to drive new cases globally, companies and institutions have continued development of interventions for the virus.
Potential FDA Approval on the Way for Amylyx’s AMX0035 in ALS Ahead of Time
On September 15, Amylyx Pharmaceuticals announced that its bid to submit a new drug application (NDA) for its amyotrophic lateral sclerosis (ALS) investigational asset AMX0035, using data from the Phase II CENTAUR trial, has been permitted following recent discussions with the FDA.
Resumed trials continue to increase further
Since the beginning of the Covid-19 pandemic, the number of resumed trials has increased, with the US having the largest number.
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
Seelos Therapeutics’ intranasal ketamine offers promise in treating suicidality
On July 6, Seelos Therapeutics announced that the first patient has been dosed in the second part of their registrational, double-blind, placebo-controlled study of SLS-002 (intranasal racemic ketamine) for acute suicidal ideation and behavior (ASIB) in patients with major depressive disorder (MDD).
ASCO 2021: LAG-3 is now a validated target in Melanoma
At the virtual 2021 annual American Society of Clinical Oncology conference (ASCO 2021) on June 4–8, results from the Phase III RELATIVITY-047 study for Bristol-Myers Squibb’s (BMS) relatlimab were presented.
ASCO 2021: Compelling data For Ciltacabtagene Autoleucel in multiple myeloma
At the virtual 2021 annual American Society of Clinical Oncology conference (ASCO 2021) on June 4–8, Johnson & Johnson (J&J) presented updated results from its Phase I/II study CARTITUDE-1 in relapsed/refractory (R/R) multiple myeloma (MM).
Microbiome therapeutics rising as potential immuno-oncology agents
Clinical data and industry partnerships have fueled a shift in perception of the microbiome-based therapeutic market from nascent to developing, with GlobalData forecasting the market to be worth $1.554B in 2026.
Interim Data from UK Com-COV study suggest higher reactogenicity but remain inconclusive
The Oxford-led Phase II Com-COV trial is investigating immune responses in patients who have been given heterologous prime-boost vaccine schedules using AstraZeneca’s Vaxzevria (ChAdOx1 nCov-19) and Pfizer’s Comirnaty (BNT162b2) COVID-19 vaccines.